AC
ANRO icon

AlphaCore Capital’s Alto Neuroscience ANRO Stock Holding History

AlphaCore Capital’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,000
Closed -$356K – 1531
2025
Q4 		$356K Buy
20,000
+10,000
+100% +$126K 0.01% 733
2025
Q3 		$40.2K Sell
10,000
-10,000
-50% -$33.2K ﹤0.01% 889
2025
Q2 		$44K Buy
20,000
+10,000
+100% +$23.8K ﹤0.01% 831
2025
Q1 		$22.7K Buy
+10,000
New +$35.8K ﹤0.01% 649

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AlphaCore Capital's ANRO Position: Q1 2026 in Review

AlphaCore Capital sold out of Alto Neuroscience (ANRO) in Q1 2026, closing a stake of 20,000 shares — an estimated $356K sold.

AlphaCore Capital first reported a position in ANRO in Q1 2025 and held it in 4 quarters. The position peaked at $356K in Q4 2025. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • AlphaCore Capital reported no remaining Alto Neuroscience position as of Q1 2026 after selling out during the quarter.
  • AlphaCore Capital sold 20,000 Alto Neuroscience shares in Q1 2026, an estimated $356K.
  • AlphaCore Capital first reported a position in Alto Neuroscience in Q1 2025 and held it in 4 quarters.
  • AlphaCore Capital's Alto Neuroscience position peaked at $356K in Q4 2025.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on AlphaCore Capital's 13F filing for Q1 2026, filed 15 May 2026.